Medical Affairs was created as a support function to marketing and sales but has evolved over the last decade into the third pillar of pharmaceutical and biotechnology companies. Today, with the breadth and depth of diverse data sources, rapid changes in technology, increasing scientific complexity of treatments, and regulatory and economic trends, organizations that cultivate strategic and diversely talented medical teams have the competitive advantage.
Forward looking organizations are building the medical affairs teams of the future. These teams are breaking down traditional silos and developing capacities to evolve data generation across clinical development, HEOR and real-world evidence. They are evolving to effectively translate, not only the clinical, but also the economic impact to increasingly important stakeholders, especially payer decision-makers with unprecedented size and scale and knowledge-empowered patients.
In a day of rapid scientific and medical advancement, equity, and economic concerns, the pharmaceutical industry requires strategic medical leadership. Required are highly skilled and empowered medical affairs teams that harness data and insights to help physicians, payers, and patients choose the right medication, at the right time, to drive meaningful impact for individual patients and societal health outcomes.
Join us for an overview from McKinsey of how medical affairs has evolved over time and where it is headed followed by a panel discussion on how life sciences companies of all sizes can best hire, develop, and leverage these skilled professionals for a competitive advantage.
Sponsored by the MassBio MarCom and Commercial Forum Working Group.
5 авг 2024
